However, there are a number of unknowns, including (a) whether and how the proinflammatory effects of PARP1 impact cancer-associated inflammation; (b) whether inhibition of cancer-associated inflammation by PARPis provides therapeutic benefits, and (c) how spatiotemporal factors and tumor-specific differences modulate such potential anticancer effects. This evidence concerns the gene PARP1 and cancer.